Sunmax Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2018
November 11, 2018 at 01:12 pm
Share
Sunmax Biotechnology Co., Ltd. announced earnings results for the third quarter ended September 30, 2018. For the third quarter, the company announced total revenue was TWD 77.693 million compared to TWD 48.071 million a year ago. Sales was TWD 77.693 million compared to TWD 48.071 million a year ago. Operating income was TWD 17.090 million compared to operating loss of TWD 774,000 a year ago. Net income was TWD 13.723 million compared to TWD 4.086 million a year ago. Basic earnings per share was TWD 0.25 compared to TWD 0.08 a year ago. For the nine months, total revenue was TWD 205.374 million compared to TWD 136.749 million a year ago. Sales was TWD 205.374 million compared to TWD 136.749 million a year ago. Operating income was TWD 35.661 million compared to TWD 8.688 million a year ago. Net income was TWD 44.763 million compared to TWD 11.656 million a year ago. Basic earnings per share was TWD 0.83 compared to TWD 0.22 a year ago.
SunMax Biotechnology Co., Ltd. is a Taiwan-based company principally engaged in research, development, production and distribution of collagen implants and related products. The Company's major products include collagen, collagen implants, microfiber collagen hemostat, collagen absorbable hemostat pads, healthcare products, as well as medical collagen application equipment. Its products are applied in medical and beauty care industrials. The Company distributes its products principally in Taiwan, Mainland China and other regions.